Cargando…
EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747408/ http://dx.doi.org/10.1016/j.jval.2022.09.812 |
| _version_ | 1784849590758932480 |
|---|---|
| author | Sutton, K Miller, P Branscombe, N Mittal, M Browne, C Arnetorp, S Henry, T Breslin, K Bungey, G Quint, J Montgomery, H |
| author_facet | Sutton, K Miller, P Branscombe, N Mittal, M Browne, C Arnetorp, S Henry, T Breslin, K Bungey, G Quint, J Montgomery, H |
| author_sort | Sutton, K |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9747408 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97474082022-12-14 EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population Sutton, K Miller, P Branscombe, N Mittal, M Browne, C Arnetorp, S Henry, T Breslin, K Bungey, G Quint, J Montgomery, H Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747408/ http://dx.doi.org/10.1016/j.jval.2022.09.812 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Sutton, K Miller, P Branscombe, N Mittal, M Browne, C Arnetorp, S Henry, T Breslin, K Bungey, G Quint, J Montgomery, H EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population |
| title | EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population |
| title_full | EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population |
| title_fullStr | EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population |
| title_full_unstemmed | EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population |
| title_short | EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population |
| title_sort | ee572 cost-effectiveness of azd7442 (tixagevimab and cilgavimab) for pre-exposure prophylaxis against covid-19 in the immunocompromised population |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747408/ http://dx.doi.org/10.1016/j.jval.2022.09.812 |
| work_keys_str_mv | AT suttonk ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT millerp ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT branscomben ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT mittalm ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT brownec ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT arnetorps ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT henryt ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT breslink ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT bungeyg ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT quintj ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation AT montgomeryh ee572costeffectivenessofazd7442tixagevimabandcilgavimabforpreexposureprophylaxisagainstcovid19intheimmunocompromisedpopulation |